Last reviewed · How we verify
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine is a Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite Biologic drug developed by RemeGen Co., Ltd.. It is currently in Phase 3 development for HER2-positive gastric or gastroesophageal junction cancer (phase 3).
This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage.
This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage. Used for HER2-positive gastric or gastroesophageal junction cancer (phase 3).
At a glance
| Generic name | Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine |
|---|---|
| Sponsor | RemeGen Co., Ltd. |
| Drug class | Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite |
| Target | HER2, PD-1, DNA (via oxaliplatin and capecitabine) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Disitamab vedotin is an anti-HER2 antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cells. Tislelizumab is a PD-1 inhibitor that relieves immune checkpoint suppression to enhance anti-tumor immunity. Oxaliplatin and capecitabine provide additional chemotherapy-mediated cytotoxicity and synergistic anti-tumor effects in the combination regimen.
Approved indications
- HER2-positive gastric or gastroesophageal junction cancer (phase 3)
Common side effects
- Nausea
- Diarrhea
- Neutropenia
- Anemia
- Fatigue
- Immune-related adverse events
Key clinical trials
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (PHASE3)
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine CI brief — competitive landscape report
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI
Frequently asked questions about Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
What is Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine?
How does Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine work?
What is Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine used for?
Who makes Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine?
What drug class is Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine in?
What development phase is Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine in?
What are the side effects of Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine?
What does Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine target?
Related
- Drug class: All Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite drugs
- Target: All drugs targeting HER2, PD-1, DNA (via oxaliplatin and capecitabine)
- Manufacturer: RemeGen Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive gastric or gastroesophageal junction cancer (phase 3)
- Compare: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine vs similar drugs
- Pricing: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine cost, discount & access